Does cytoplasmic AR-V7 circulating tumor cell (CTC) detection add utility in predicting AR pathway inhibitor benefit in men with mCRPC? A retrospective analysis of the PROPHECY study.

Authors: Santosh Gupta, Susan Halabi, Siyuan Guo, Jane McKenzie, Daniel J. George, David M. Nanus, Russell Zelig Szmulewitz, Daniel Costin Danila, Rick Wenstrup, Emmanuel S. Antonarakis, Andrew J. Armstrong

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.5043

Source: Full article

---

Abstract

5043